AvenCell has developed proprietary next generation immunotherapy platforms that promise significant advantages over existing immunotherapies. We achieve this by making the most powerful therapies switchable, adaptable, persistent and readily available.
Our Universal Switchable CAR platform combines the best of two worlds – the powerful anti-tumor response of CAR-T in combination with flexible soluble adaptors termed targeting modules (TM). This adds a clinically validated and unprecedented safety profile to our CAR-T, prevents their exhaustion and allows for a flexible targeting of multiple antigens in hematologic malignancies and solid tumors to overcome tumor escape and deepen responses.
AvenCell’s Allogeneic platform, licensed from Intellia Therapeutics, Inc., is unique in that it is engineered to fully overcome graft-versus-host disease as well as graft rejection by host T and NK cells. Aim is to provide highly effective “off-the-shelf” cell therapies at significantly reduced costs. The use of healthy donor T cells combined with the novel combination of three CRISPR/Cas9 edits is intended to provide a safe and persistent cell product with durable efficacy. AVC-201 is the first investigational cell therapy that utilizes this differentiated Allogeneic technology and is currently in early clinical development.
VP, Clinical Operations
Susan is the Vice President, Clinical Operations for Avencell; she brings over 30 years of experience in Global Clinical Operations to AvenCell’s Clinical Operations team. Prior to joining Avencell, Susan had multiple senior level roles within the Biotech, Pharmaceutical and CRO organizations. Susan has experience in leading clinical operations teams to successful study execution and multiple global regulatory submissions. Susan is a graduate of the University of Wisconsin-Milwaukee with a Bachelor of Science in Medical Technology.
Chief Executive Officer
Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you.
Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing? Leave your details and I’ll get back to you.
